Metacrine Inc., a San Diego company developing new therapies for liver and gastrointestinal diseases, has inked a loan and security agreement worth up to $50 million with the private equity-backed health care financier K2 Healthventures (K2HV). Metacrine has raised almost $125 million since its founding. New nondilutive funding will support a robust clinical development plan in 2020, CEO Ken Song told BioWorld.